Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 7, 2012, Pages 670-679

  Rowe, I A ^a,b   Houlihan, D D ^a,b   Mutimer, D J ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FIBROSIS; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MODELS, THEORETICAL; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SERINE PROTEINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866254614     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12018     Document Type: Article

References (39)

1. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Seeff LB,. Natural history of hepatitis C. Am J Med 1999; 107: 10S-5S.
3. Kanwal F, Hoang T, Kramer JR, et al,. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.
4. Yudkin JS, Lipska KJ, Montori VM,. The idolatry of the surrogate. BMJ 2011; 343: d7995.
5. Rowe IA, Mutimer DJ,. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011; 343: d6972.
6. Lange CM, Sarrazin C, Zeuzem S,. Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14-28.
7. Pawlotsky JM,. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-51.
8. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
9. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
10. Poordad F, McCone JJ, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
11. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM,. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl.): S88-100.
12. Bacon BR, Khalid O,. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. Liver Int 2012; 32 (Suppl. 1): 51-3.
13. Ramachandran P, Fraser A, Agarwal K, et al,. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-62.
14. Jacobson IM, Pawlotsky JM, Afdhal NH, et al,. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19 (Suppl. 2): 1-26.
15. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J,. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
17. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
18. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
19. Foster GR, Zeuzem S, Andreone P, et al,. Subanalyses of the trlaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null response categorisation. J Hepatol 2011; 54: S3.
20. Telaprevir (Incivo) Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/25038/spc. Last accessed June 2. Accessed June 2, 2012.
21. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS,. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-8.
22. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al,. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
23. Pauker SG, Kassirer JP,. Decision analysis. N Engl J Med 1987; 316: 250-8.
24. Plevritis SK,. Decision analysis and simulation modeling for evaluating diagnostic tests on the basis of patient outcomes. AJR Am J Roentgenol 2005; 185: 581-90.
25. El-Serag HB, Talwalkar J, Kim WR,. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology 2010; 52: 403-7.
26. Moore A, McQuay H,. Numbers needed to treat derived from meta analysis. NNT is a tool, to be used appropriately. BMJ 1999; 319: 1200.
27. Hezode C, Dorival C, Zoulim F, et al,. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non-responders. First results of the French early access program (ANRS CO20-CUPIC) in real-life setting. GAJ 2011; 7: 54.
28. Massoumi H, Elsiesy H, Khaitova V, et al,. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation 2009; 88: 729-35.
29. Everson GT, Trotter J, Forman L, et al,. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
30. Rowe IA, Armstrong M, Houlihan D,. Prioritising treatment experienced patients with hepatitis C infection for treatment with telaprevir. A number needed to treat approach. Hepatology 2012; 55: 1644-5.
31. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
32. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
33. AASLD. AASLD: Response to Comments on An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection. Available at: http://www.aasldorg/ practiceguidelines/Pages/hepccomments. Last accessed June 20. Accessed June 20, 2012.
34. Everson GT, Shiffman ML, Hoefs JC, et al,. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther 2009; 29: 589-601.
35. Everson GT, Balart L, Lee SS, et al,. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008; 27: 542-51.
36. Hezode C, Castera L, Roudot-Thoraval F, et al,. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 656-63.
37. DiBonaventura M, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W,. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011; 14: 253-61.
38. Su J, Brook RA, Kleinman NL, Corey-Lisle P,. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010; 52: 436-42.
39. Alazawi W, Cunningham M, Dearden J, Foster GR,. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-55.